NCT06671314

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Adoption of Novel Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 42,494 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.

Conditions

• Heart Failure With Reduced Ejection Fraction
• Heart Failure With Preserved Ejection Fraction

Timeline

• Start date: 2022-06-02
• Primary completion: 2022-10-31
• Completion: 2022-10-31
• First posted: 2024-11-04
• Last updated: 2024-11-04

Locations

1 site across 1 country: United States